RxDoctor Payments Data

Sung Un Hall, PA

Medical · Wichita, KSNPI 1003925272

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.0% of the total across 193 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,092 and has fallen 91.4% since, to $94 in 2025.

$3,732in general payments, 2019–2025

Across 193 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$870
  • Amgen$516
  • E.r. Squibb & Sons, L.L.C.$504
  • Novartis$446
  • Sun Pharmaceutical Industries Inc.$433
  • Johnson & Johnson$209
  • plus $754 from 17 others

What the payments were for

  • Food & beverage$3,58396%
  • Education$1494%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,732 in reported general payments places this provider in the 80th percentile of 205 medical providers in Kansas.

See all medical providers in Kansas

Medicare billing

Part B allowed, 2024
$185,341
Medicare patients
689
Services billed
4,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast26$101,195
Humira PenAdalimumab12$81,514
Clobetasol Propionate74$4,258
Ketoconazole77$2,168
Fluorouracil12$1,292
Doxycycline Hyclate62$740
Fluocinonide11$661
Clindamycin Phosphate16$518
Metronidazole12$422
Triamcinolone Acetonide82$385
Imiquimod17$332
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip17$316
Mupirocin11$85
Hydrocortisone14$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$516$101,19526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 205 medical providers in Kansas.

Other medical in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →